HydroxycarbamideDel (5q)-positive myelodysplastic syndrome: case report

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2017年 / 1647卷 / 1期
关键词：
D O I：
10.1007/s40278-017-28848-y
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：156 / 156
相关论文
共 50 条
  • [41] Bone marrow morphology in myelodysplastic syndrome associated with isolated del(5q)
    Naresh, Kikkeri N.
    Reid, Alistair
    AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (08) : 609 - 610
  • [42] HETEROGENEITY IN CYTOGENETIC AND CLINICAL FEATURES OF PATIENTS WITH MYELODYSPLASTIC SYNDROME AND DELETION 5Q
    Papaioannou, G.
    Athanasiadou, A.
    Gavriilaki, E.
    Bousiou, Z.
    Iskas, M.
    Papathanasiou, M.
    Stavroyianni, N.
    Sakellari, I.
    Anagnostopoulos, A.
    HAEMATOLOGICA, 2016, 101 : 505 - 505
  • [43] Azacitidine Treatment of Lenalidomide-Resistant Myelodysplastic Syndrome with Deletion 5q
    Komrokji, Rami S.
    Al Ali, Najla H.
    Padron, Eric
    Lancet, Jeffrey E.
    List, Alan F.
    BLOOD, 2011, 118 (21) : 1195 - 1195
  • [44] Translocations involving chromosome 5q found in patients with myelodysplastic syndrome (MDS)
    Michalova, K
    Zemanova, Z
    Brezinova, J
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 1254 - 1254
  • [45] Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion
    Garderet, Laurent
    Ziagkos, Dimitris
    Van Biezen, Anja
    Lacobelli, Simona
    Finke, Juergen
    Maertens, Johan
    Volin, Liisa
    Ljungman, Per
    Chevallier, Patrice
    Passweg, Jakob
    Schaap, Nicolaas
    Beelen, Dietrich
    Nagler, Arnon
    Blaise, Didier
    Poire, Xavier
    Yakoub-Agha, Ibrahim
    Lenhoff, Stig
    Craddock, Charles
    Schots, Rik
    Rambaldi, Alessandro
    Sanz, Jaime
    Jindra, Pavel
    Mufti, Ghulam J.
    Robin, Marie
    Kroeger, Nicolaus
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (03) : 507 - 513
  • [46] Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer
    Ebert, B. L.
    LEUKEMIA, 2009, 23 (07) : 1252 - 1256
  • [47] RPS14 EXPRESSION IN MYELODYSPLASTIC SYNDROME WITHOUT 5Q DELETION
    Quiroz, K.
    Guillen, C.
    Ayala, R.
    Martinez, J.
    HAEMATOLOGICA, 2015, 100 : 480 - 480
  • [48] Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?
    Gorshein, Elan
    Weber, Urs M.
    Gore, Steven
    EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (03) : 233 - 239
  • [49] Efficacy to lenalidomide treatment and complete cytogenetic remission in a case of myelodysplastic syndrome with del(5q) and del(9q)
    Xiong, Bei
    Liu, XinYue
    Zou, Ping
    Fan, LiHua
    Chen, WanXin
    Li, WeiMing
    Liu, Lin
    LEUKEMIA RESEARCH, 2010, 34 (07) : E169 - E172
  • [50] DELETION OF 5Q BY T(5-17) IN THERAPY-RELATED MYELODYSPLASTIC SYNDROME
    VANDENBERGHE, EA
    MECUCCI, C
    DELANNOY, A
    VANDENBERGHE, H
    CANCER GENETICS AND CYTOGENETICS, 1990, 48 (01) : 49 - 52
12345